Carlos Solorzano, PhD

Carlos is a Principal for the private equity strategy at Ally Bridge Group focused on investments in biotech. Before joining Ally Bridge, Carlos was in the investment teams at Section 32 and Pivotal bioVenture Partners focused on private biotech companies. Before his career in private equity, Carlos was in the BD and Corporate Strategy team at Ultragenyx and was a Senior Associate in the equity research teams at Deutsche Bank and Oppenheimer & Co. Carlos has a BS in Chemical Engineering from Cal Poly Pomona, earned a PhD in Pharmacology from UC Irvine, and was an NIH postdoctoral scholar at UC San Francisco.